ArticleOncotarget2016
eIF5B increases ASAP1 expression to promote HCC proliferation and invasion.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 32 citations in OpenAlex.
- ElF5B as a prognostic biomarker and its correlation with infiltrating immune cells in liver cancer.Genes & genomics · 2025Article
- ASAP1 and ARF1 Regulate Myogenic Differentiation in Rhabdomyosarcoma by Modulating TAZ Activity.Molecular cancer research : MCR · 2025Article
- Translational Control of Metabolism and Cell Cycle Progression in Hepatocellular Carcinoma.International journal of molecular sciences · 2023Review
- ASAP1 activates the IQGAP1/CDC42 pathway to promote tumor progression and chemotherapy resistance in gastric cancer.Cell death & disease · 2023Article
- Comprehensive analysis of metabolic pathway activity subtypes derived prognostic signature in hepatocellular carcinoma.Cancer medicine · 2023Article
- Translational regulation of cell invasion through extracellular matrix-an emerging role for ribosomes.F1000Research · 2023Review
- A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.BMC cancer · 2022Article
- PAIP1 is a novel oncogene in human hepatocellular carcinoma.Discover oncology · 2022Article
- Review
- Network analysis of hepatocellular carcinoma liquid biopsies augmented by single-cell sequencing data.Frontiers in genetics · 2022Article
- Clinicopathological Implications of ASAP1 Expression in Hepatocellular Carcinoma.Pathology oncology research : POR · 2022Article
- IGF2BP3-induced activation of EIF5B contributes to progression of hepatocellular carcinoma cells.Oncology research · 2022Article
- Translational Regulation in Hepatocellular Carcinogenesis.Drug design, development and therapy · 2021Review
- Established and Emerging Regulatory Roles of Eukaryotic Translation Initiation Factor 5B (eIF5B).Frontiers in genetics · 2021Review
- Eukaryotic initiation factor 5B (eIF5B) provides a critical cell survival switch to glioblastoma cells via regulation of apoptosis.Cell death & disease · 2019Article
- The role of circular RNA hsa_circ_0085616 in proliferation and migration of hepatocellular carcinoma cells.Cancer management and research · 2019Article
- Identification of two novel host proteins interacting with Toxoplasma gondii 14-3-3 protein by yeast two-hybrid system.Parasitology research · 2018Article
- A pan-cancer genome-wide analysis reveals tumour dependencies by induction of nonsense-mediated decay.Nature communications · 2017Article
- CXCL10 accelerates EMT and metastasis by MMP-2 in hepatocellular carcinoma.American journal of translational research · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death worldwide. Despite the therapeutic advances that have been achieved during the past decade, the molecular pathogenesis underlying HCC remains poorly understood. In this study, we discovered that increased expression eukaryotic translation initiation factor 5B (eIF5B) was significantly correlated with aggressive characteristics and associated with shorter recurrence-free survival (RFS) and overall survival (OS) in a large cohort. We also found that eIF5B promoted HCC cell proliferation and migration in vitro and in vivo partly through increasing ASAP1 expression. Our findings strongly suggested that eIF5B could promote HCC progression and be considered a prognostic biomarker for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.